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The impressive impact of cisplatin on cancer on one side and severe side eﬀects, as well as the development of drug resistance
during treatment on the other side, were the factors motivating scientists to design and synthesize new more potent analogues
lacking disadvantages of cisplatin. Platinum(IV) complexes represent one of the perspective groups of platinum-based drugs. In
this review, we summarize recent ﬁndings on both in vitro and in vivo eﬀects of platinum(IV) complexes with adamantylamine.
Based on a literary overview of the mechanisms of activity of platinum-based cytostatics, we discuss opportunities for modulating
the eﬀects of novel platinum complexes through interactions with apoptotic signaling pathways and with cellular lipids, including
modulations of the mitochondrial cell death pathway, oxidative stress, signaling of death ligands, lipid metabolism/signaling, or
intercellular communication. These approaches might signiﬁcantly enhance the eﬃcacy of both novel and established platinum-
based cytostatics.
Copyright © 2008 Alois Kozub´ ık et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Platinum-based drugs are widely used anticancer agents
with a broad range of antitumor activities. Cisplatin [cis-
diamminedichloroplatinum(II)] (see Figure 1) has a signif-
icant activity in ovarian, testicular, bladder, head and neck,
and lung cancer, where it is most commonly used in combi-
nation with other drugs [1]. Thus, it has become one of the
most successful anticancer drugs used worldwide in almost
50% of solid tumor chemotherapies. Although the initial re-
sponse rates can be high with cisplatin-based regimen, the
clinical utility of the drug is often limited by the onset of ac-
quired or intrinsic resistance [2, 3] and the number of side
eﬀects such as kidney damage, vomiting/nausea, and neuro-
toxicity [4].Theresistanceoftumorcellstocisplatin remains
a major cause of treatment failure in cancer patients, while
the high toxicity of cisplatin limits the dose that can be given
to patients. Cancer cell resistance to platinum chemothera-
peutic drugs therefore remains a major obstacle and demon-
strates a need for alternatives. For this reason, vast eﬀorts
are committed to develop novel platinum-based complexes
whichmightovercometheshortcomingsofcisplatin.Theul-
timateaimistoﬁndandcharacterizeplatinum-basedderiva-
tives with higher antitumor activity, which display a more
tolerabletoxicologicproﬁleandovercomeresistanceinmany
tumor types. A second alternative approach sought is to de-
velop a more eﬃcient combination treatment of biologic re-
sponse modiﬁers together with chemotherapeutic platinum
drugs.
The enormous eﬀorts of a number of research teams
have borne fruit in two derivatives, carboplatin (cis-diam-
mine-(1,1-cyclobutanedicarboxylato)platinum(II))and,more
recently, the so-called “third generation” platinum drug
oxaliplatin (trans—R,R.cyclohexane-1,2-diammine)oxalato-
platinum(II)). Both compounds are eﬀective in colon cancer
treatment and are currently clinically approved worldwide2 Metal-Based Drugs
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Figure 1: Chemical structures of cisplatin [cis-diamminedichloroplatinum(II)], LA-9 [(SP-4-3)-(1-adamantylamine)amminedichloro-
platinum(II)], and LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine) amminedichloroplatinum(IV)].
[5, 6]. Several other platinum-based drugs have gained
regionally limited approval: Nedaplatin (Japan), SKI2053R
(South Korea), and Lobaplatin (China).
Although over 1000 complexes have been studied so far,
only 10–20% of them turned out to be active against can-
cer cells in preclinical studies [7]. These include, for ex-
ample, satraplatin which is currently in the third phase
of clinical evaluation [8]. A complementary approach also
promises to employ biologic modiﬁers such as cytokines,
lipids, and other molecules in order to increase the eﬃcacy
of both traditional and novel platinum-based drugs. Adju-
vant biochemotherapy with cytokines, such as interleukin-2
or interferon-alpha may increase response rates in patients
[9], thus improving their eﬃciency, although regimen treat-
ments must be selected carefully in order to reduce unde-
sirable eﬀects. Similar to cytokines, lipids, and their deriva-
tives, drugs interfering with metabolism of lipid compounds
or dietary supplements may provide additional beneﬁts dur-
ing the treatment with platinum-based drugs, including re-
duced side eﬀects of chemotherapy or increased toxicity to-
wards tumor cells [10–14]. The present review is intended
to provide an overview of some opportunities opened for
innovative therapeutic strategies involving both traditional
and novel platinum complexes, with particular emphasis on
the novel class of anticancer platinum(IV) complexes with
adamantylamine, which have been intensively studied in our
laboratories during recent years.
2. DEVELOPMENT OF PLATINUM(IV) COMPLEXES
WITH ADAMANTYLAMINE AND THEIR IN
VITRO/IN VIVO EFFECTS
Recently, ˇ Z´ ak et al. designed and synthesized a series of
novel platinum(II) and platinum(IV) complexes with
amino derivatives of adamantane as one of its ligands: (SP-
4-3)-(1-adamantylamine)amminedichloroplatinum(II),
coded as LA-9, and (OC-6-43)-bis(acetato)(1-adamantyl-
amine)amminedichloroplatinum(IV), coded as LA-12 (see
Figure 1 ). LA-9 represents a four-coordinate(II), and LA-12
an octahedral six-coordinate platinum complex containing
a bulky nonleaving hydrophobic (lipophilic) ligand—
adamantylamine [15]. Since the early studies by Rosenberg
et al. [16] it has been known that platinum(IV) as well as
platinum(II) complexes can display antitumor properties.
In addition, platinum(IV) complexes are much more inert
to ligand substitution reactions than are their platinum(II)
counterparts [17], and it is generally accepted that reduction
to the lower oxidation state platinum(II) is essential for the
anticancer activity of the platinum(IV) complex [18, 19].
Currently, clinical trials of the platinum(IV) derivative
LA-12 are in progress and some promising results have been
shown. LA-12 has been evaluated in a panel of preclinical
studies including in vitro and in vivo antitumor eﬃcacy
and toxicologic and pharmacokinetic studies [20, 21]. In
both murine ADJ/PC6 plasmacytoma and a human A2780
ovarian carcinoma tumor model, higher in vivo antitumor
activity of a single dose as well as of repeated doses was
observed, compared to cisplatin and the other platinum(IV)
complex—satraplatin (JM216, the ﬁrst orally administered
platinum(IV) drug currently evaluated in clinical trials)
[21]. Interestingly, the acute toxicity of LA-12 in mice is
relatively low and the eﬀective dose is comparable to that of
cisplatin and higher than that of satraplatin [21].
These highly interesting compounds were also success-
fully tested in our laboratories. We have demonstrated
that LA-9 and LA-12 display a higher hydrophobicity than
cisplatin and exert a higher cytotoxicity than satraplatin
(JM216) in the in vitro tests on a panel of 14 cancer cell lines
of various origin, and a diﬀerent sensitivity to cisplatin, in-
cluding both A2780 (cisplatin-sensitive) and A2780cis (with
acquired cisplatin resistance) ovarian cancer cells, breast car-
cinoma, colon cancer, lung carcinoma, and leukemia cells
lines, many of which are refractory to cisplatin treatment
[22, 23]. In A2780cis-resistant cells, for example, the IC50
values were 1.4 and 24.23μM for LA-12 and cisplatin, re-
spectively, with LA-12 being eﬀective at the dose approxi-
mately equal to cisplatin IC50 in parental A2780 cells, thus
proving that LA-12 may successfully counter the acquired re-
sistence in vitro [22]. The IC50 value for LA-12 in A2780 was
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in nontransformed rat liver epithelial cells, suggesting that
it is not overtly toxic in nontumorigenic cells [24]. Interest-
ingly, we found strong diﬀerences between the eﬀects of plat-
inum(IV) complex—LA-12 and platinum(II) derivatives—
LA-9 and cisplatin on cytokinetic parameters in SK-OV-3
cells (with intrinsic cisplatin resistance) [25]. Apparently,
both LA-12 and LA-9 are eﬀective in considerably lower con-
centrations than cisplatin and can overcome both acquired
and intrinsic resistance to cisplatin. Thus, the mechanisms
of the eﬀects of these compounds should be further investi-
gated, as several recent studies have demonstrated that LA-
12 may have unique eﬀects which could be responsible for its
high eﬃciency [24, 26].
3. A SEARCH FOR MECHANISMS OF ACTION
OF NOVEL PLATINUM COMPLEXES
The activity of the “classical” cisplatin is generally accepted
as being due to its ability to form adducts with DNA (inter-
and intrastrand DNA cross-links) and causing DNA strand
breaks in the nucleus [27, 28]. Subsequently, interference
with normal transcription and/or DNA replication mecha-
nisms [29] are its characteristic biological eﬀects, leading to
either repair of the DNA damage and cell survival, or ac-
tivation of the irreversible cell death program as a conse-
quence. Indeed, early observations have shown that cells de-
ﬁcientinDNArepairpathwaysarehypersensitivetocisplatin
[29, 30], suggesting that cisplatin and other platinum-based
complexes bind DNA.
On the other hand, cisplatin may react with many other
cellular components that have nucleophilic sites such as
RNA, proteins, membrane phospholipids, cytoskeletal ﬁla-
ments, and thiol-containing molecules [31]. Although cis-
platin can react with a variety of cellular macromolecules
and there is strong evidence that the most important target
is DNA [27], it is estimated that less than 1% of the cisplatin
molecules that enter the cell actually bind nuclear DNA, with
most of them ending up binding other biomolecules [32].
Thisindicatesthatincreasedattentionshouldalsobefocused
on the discovery of mechanisms of action of platinum-based
drugs, which are diﬀerent from those primarily based on
DNAdamage.Suchmechanismscouldsubstantiallyinterfere
withtheotherintracellularsignalingpathwaysregulatingcell
growth and death.
4. UNIQUE PROPERTIES OF NOVEL
PLATINUM DERIVATIVES
Thecytotoxicityofplatinum-basedanticancerdrugsisthere-
fore a result of many events, beginning with the intracel-
lular accumulation and proceeding through detoxiﬁcation
by intracellular thiol-containing molecules, DNA modiﬁca-
tion, and cellular responses to DNA damage. Modiﬁcation
of the leaving group(s) in platinum complexes inﬂuences
both biodistribution and the general toxicity. On the con-
trary, modiﬁcation of the amine ligand(s) will inﬂuence the
anticancerproperties, since thenonleaving amine ligands are
the reason for structurally diﬀerent DNA or DNA/protein
adducts. The hydrophobicity (lipophilicity) and bulkiness of
the nonleaving amine ligand signiﬁcantly aﬀect several fac-
tors (permeation through the cell membrane, reactivity to-
wardsDNAandthiols,andrecognitionofDNAadducts)that
areresponsibleforcytotoxicpotentialofplatinumcomplexes
on the molecular and cellular levels. In various platinum(II)
complexes,theincreaseofligandhydrophobicityispositively
correlated with the increase of the cytotoxic eﬀect [33].
It is therefore interesting that a similar correlation was
found within a homologous series of platinum(IV) com-
plexes[23].Thehigherhydrophobicity oftheplatinumcom-
plexes enhanced their penetration through the cell mem-
brane and increased their accumulation inside the cancer
cells. The high intracellular concentrations of platinum(IV)
drugs,togetherwiththeirreactivitytowardsDNA,mayaccel-
erate the production of various platinum-DNA or platinum-
DNA/protein adducts, which are more or less endowed with
the ability to trigger apoptosis or necrosis in target cells. The
hydrophobic complex LA-12 is a good example of a plat-
inum(IV) complex with a bulky hydrophobic ligand, en-
hancingaccumulationincancercellsandtriggeringrapidcell
death in both cisplatin-sensitive and cisplatin-resistant cell
lines [22, 25]. LA-12 proved to be very toxic against various
cancer cells representing diﬀerent types of cancer and em-
ploying diﬀerent mechanisms of resistance towards cisplatin
[23].
In comparison to cisplatin and satraplatin (JM-216), LA-
12 represents a complex with a very high hydrophobicity
due to the presence of adamantylamine ligand. Moreover,
the symmetry of the hydrophobic adamantyl moiety light-
ens penetration of the whole complex through biological
membranes. This theoretical presumption has been proven
experimentally in cisplatin-sensitive and cisplatin-resistant
cell lines A2780 and A2780/cisR, respectively. Platinum up-
take in sensitive and resistant A2780 cell lines was more than
one order of a magnitude lower for cisplatin in comparison
with LA-12. Moreover, accumulation of LA-12 in cisplatin-
resistant cells was not decreased in the range having an eﬀect
on biological activity [26].
4.1. EffectsofLA-12incisplatin-resistantcells
In all human cancer cell lines studied so far, it seems appar-
ent that cisplatin resistance is a multifactorial process, being
a result of decreased drug uptake, increased DNA repair and
tolerance to DNA lesions, slow cell proliferation and replica-
tive bypass, and/or cytosolic drug inactivation. We cannot
exclude that LA-12 is a substrate for some of multidrug resis-
tance proteins (MRP; MDR) and P-glycoprotein (P-gp), but
the low cross-resistance with cisplatin together with high ac-
cumulation in cisplatin-resistant cancer cell line A2780/cisR
seem to imply that MRP/MDR systems are of secondary im-
portance in comparison with increased ability of hydropho-
bic LA-12 to penetrate through biological membranes.
Ovarian epithelial cancer cell line A2780 is a well-
described model for studies on cisplatin resistance. The re-
sistant sublines, prepared by gradual treatment by cisplatin,
are available and several mechanisms of resistance have been
described.Itseemsthatthecisplatin-resistantA2780sublines
represent the type of cisplatin-resistant cells, in which several4 Metal-Based Drugs
Table 1: Comparison of the cytotoxicity of cisplatin, LA-12 and
satraplatin(JM-216)againstcisplatin-resistanttumorcelllines.Val-
uesofIC50 werecalculatedfor24hourexposuretime(adaptedfrom
Tur´ anek et al. Anticancer Drugs. 2004,15:537-543).
Cancer cell line IC50 (μM)
Cisplatin LA-12 Satraplatin
K562 >80 3 63
KG-1 48 2 63
ML-2 >80 1 56
B16 >80 6 >80
HT-29N >80 12 >80
HT-29 50 8 70
HCT116 >80 9 >80
A427 63 6 13
HBL100 63 6 >80
MCF-7 71 8 70
CPRL23/CTR >80 25 56
A2780 7 4 63
A2780cis40 40 3 40
A2790cis90 >80 7 63
mechanisms of resistance are well orchestrated. An organic
anion pump that could be involved in cisplatin resistance
is a multidrug resistance protein 2 (MRP2). High expres-
sion of MRP2 was found in A2780/cis70 cell line, together
with increased levels of glutathione [34]. Cisplatin-resistant
A2780/cis70 cells demonstrated enhanced eﬄux of ciplatin
as compared to parent A2780 cells. Enhanced DNA repair
was also observed in A2780/cis70 cells and this mechanism
has been shown to be responsible for cisplatin resistance
[35].Expressionofalltheabove-mentionedsystemsgivesthe
cisplatin-resistant A2780 sublines a remarkable capability to
survive the attack of cisplatin. LA-12 demonstrated also very
low cross-resistance in both A2780/cis40 and A2780/cis90
sublines. There was no cisplatin cross-resistance with inter-
mediate resistant A2780/cis40. In contrast, cross-resistance
has been observed for another new generation platinum(II)
complex ZD0473 (formerly known as JM473, AMD473) in
A2780 and A2780/cis40 cells [36]. Interestingly, we have
observed a substantial cross-resistance for satraplatin (JM-
216), using a panel of cisplatin-resistant cancer cell lines (see
Table 1).
StronginhibitionofDNApolymerizationbyLA-12/DNA
adducts, enhanced persistence of these adducts due to their
less eﬃcient repair, and DNA-protein cross-linking could
be responsible for the unique cytotoxic activity of LA-12
[23,26].Therefore,increasedattentionshouldbepaidtothis
compound, with the aim to deﬁne its mechanisms of action,
as well as to search for alternative approaches improving its
anticancer activity. In the following sections, we summarize
thecurrentpossibilitiesofmodulatingtheeﬀectsofcisplatin,
which might also be employed for novel platinum-based
drugs, such as platinum(IV) derivatives with adamanty-
lamine.Ourattentionisprimarilyfocusedonsignalingpath-
ways regulating the programmed cell death (apoptosis) and
modulation of cellular lipids. For more information on other
drug-resistance mechanisms, such as MDR, the readers are
kindly requested to consult several recent excellent reviews
[37–39].
5. ACTIVATION OF SIGNALING PATHWAYS
LEADING TO CELL DEATH
In general, apoptosis is the most important form of cell
death induced in response of tumor cells to chemotherapeu-
tic agents, including platinum-based cytostatics. However,
in some cell lines, particularly those with resistance to the
drug, platinum-derived chemotherapeutics may also pro-
duce characteristic features of necrotic cell death. Moreover,
inthesamepopulationofcisplatin-treatedcells,necroticand
apoptotic cell deaths have been shown to occur simultane-
ously (for review see [40]). In addition, other death signaling
pathways may also be stimulated following cisplatin treat-
ment, ﬁnally leading to autophagy [41]. Thus, diﬀerent types
of cell death induced by the chemotherapeutic drugs have
been reported to occur, depending on the cell type and/or
drug concentration.
5.1. Apoptoticpathwaysregulatedby
anticancerdrugs
Two major distinct apoptotic pathways have been described
for mammalian cells. The intrinsic pathway is characterized
by the central role of the mitochondria in the apoptotic sig-
naling cascade. Bcl-2 family proteins are known as impor-
tant regulators at the level of these organelles. Transloca-
tion of proapoptotic proteins from mitochondria to the cy-
tosol results in caspase activation and execution of apoptosis.
This pathway functions in response to various types of intra-
cellular stress-inducing agents, DNA damage, growth factor
withdrawal, or in response to activation of death receptor-
mediated apoptosis in type II cells. On the other hand, in the
extrinsic pathway, caspase activation is initiated by the death
receptors on the surface of the so-called type I cells and this
pathway may proceed independently of mitochondria [42].
Chemotherapeutic agents are known to induce/modulate
apoptosis at the level of both intrinsic and/or extrinsic path-
way.
Emerging evidence suggests that defects or dysregulation
of diﬀerent steps of the apoptotic signaling pathways may be
an important determinant of resistance to anticancer drugs
( r e v i e w e di n[ 43, 44]). The mechanisms that inhibit propa-
gation of the apoptotic machinery induced by cisplatin may
include loss of p53 function, overexpression of Her-2/neu,
activation of PI3K/Akt pathway, overexpression of antiapop-
totic Bcl-2 protein, interference in caspase activation, and so
forth. The molecular signature deﬁning the resistant phe-
notype varies among tumors, and the number of resistance
mechanisms activated in response to selection pressures dic-
tates the overall extent of cisplatin resistance (for review see
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5.2. Interactionsofplatinum-baseddrugs
anddeathligands
The onset of resistance or cross-resistance of tumor cells to
severalchemotherapeuticdrugsisaserioustherapeuticcom-
plication.Diﬀerentagentshavebeeninvestigated withregard
to their ability to induce/modulate signaling pathways in-
volved in drug-induced apoptosis. Among them, members
of the tumor necrosis factor (TNF) family of apoptotic in-
ductors are of particular interest. These agents have been
showntobecapableoftriggering/modulatingmitochondria-
dependent and/or mitochondria-independent apoptotic
pathways inside the cell and may contribute to the po-
tentiation of apoptosis, when coadministered together with
chemotherapy [45]. Elucidation of the mechanisms involved
in these eﬀects therefore deserves further attention.
A number of studies, including our own preliminary
data, have shown that TNF-related apoptosis-inducing lig-
and (TRAIL) (an important member of the TNF family)
workssynergisticallywithsomeanticancerdrugstokillmany
types of tumor cells and eliminate resistance to such drugs.
These ﬁndings indicate that the combination of TRAIL and
chemotherapeutic drugs is potentially promising in treat-
ing refractory cancers. TRAIL can induce human cancer
cell apoptosis through the engagement of its death recep-
tors (DRs) DR4 and DR5. However, not all cancers are sen-
sitive to this cytokine. The mechanisms of modulation of
the death receptor-mediated apoptosis (induced by TRAIL)
and DR-mediated regulation in colon cancer cells have also
been studied in our laboratory [46, 47]. Recently, it has
been shown that low doses of cytotoxic drugs could restore
TRAIL-induced cell death in resistant colon and prostate
cancer cell lines [1, 48]. Ligation of TRAIL to its cognate
receptors results in receptor activation and formation of a
death-inducing signaling complex (DISC), which is respon-
sible for caspase-8 activation and further propagation of the
apoptotic signal [42]. Chemotherapeutic agents have been
shown to have a great impact on these processes.
At the level of plasma membrane, upregulation of the
DRs was shown to be responsible for cisplatin-induced sen-
sitization to DR-mediated apoptosis [49]. Chemotherapeu-
tic agents can induce a redistribution of CD95, DR4, and
DR5 in lipid rafts that accounts for the synergistic toxic-
ity of chemotherapy and DR ligands in colon carcinoma
cells [50]. An increased recruitment of Fas-associated death
domain (FADD) adaptor protein and procaspase-8 to the
TRAILDISCwasdemonstratedincoloncancercellsexposed
to cisplatin-based drugs [51]. Interestingly, phosphorylated
FADD was shown to play an essential role in the mecha-
nisms of ampliﬁcation of chemotherapy-induced apoptosis
in prostate cancer cells [52]. Furthermore, cisplatin down-
regulated the levels of c-FLIPL (a competitive inhibitor of
caspase-8 at the DISC level) in osteosarcoma cells, sensitiz-
ing them to Fas-mediated apoptosis [53].
The cisplatin-mediated potentiation of TRAIL-induced
apoptosis has been replaced at the mitochondrial level, as
demonstrated by Bid cleavage, the dissipation of mitochon-
drial membrane potential (MMP), and the release of mito-
chondrialproteinsintothecytosolofthemesotheliomalcells
[54]. Exposure of esophageal cancer cells to sublethal con-
centrations of cisplatin resulted in profound potentiation of
their susceptibility to TRAIL cytotoxicity, accompanied by
signiﬁcant activation of caspase-8, -9, and -3. Interestingly,
activation of these caspases was abrogated by overexpression
ofBcl-2orbytheselectivecaspase-9inhibitor,whichpointed
to the essential role of mitochondria-dependent signaling
cascade in this process [55]. Similarly, the mitochondria-
dependent caspase activation cascade has been shown to
play a signiﬁcant role in cisplatin-mediated potentiation of
TRAIL-inducedapoptosisinthoraciccancercells[56].These
results suggest that mitochondria could be a direct target for
the development of more reﬁned strategies to enhance the
therapeutic eﬀect of TRAIL as an anticancer agent.
6. CHEMOTHERAPY AND MITOCHONDRIA
Comparison between cisplatin, oxaliplatin, and carboplatin
eﬀects on cancer cells shows that, in addition to the extent of
nuclear DNA platination and fragmentation, impairment of
mitochondrialfunctionscouldalsobeameasureofplatinum
drug cytotoxicity [57]. Cisplatin has been shown to accumu-
late in mitochondria of cultured cells and to have eﬀects on
isolated mitochondria depending on cell type. Cisplatin and
its second generation derivatives produced marked changes
of mouse live mitochondrial morphology, enzyme activity,
Ca2+ inﬂux, and surface potential. However, these eﬀects did
not correlate with nephrotoxicity [58]. Cisplatin binds to
kidney mitochondrial proteins in treated mice and inacti-
vates the alpha-ketoglutarate dehydrogenase complex in cul-
tured LLC-PK1 cells, which is associated with drug bioacti-
vation [59]. Evaluation of mitochondrial oxygen consump-
tionusingvariouscelllinesandtumorsfrompatientsshowed
thatcisplatindoesnotdirectlydamagetheenergy-converting
mechanism of mitochondria [60]. In 3T3 and Walker 256
cells, cisplatin had acute, but reversible, eﬀects on the reor-
ganization of the intermediate ﬁlament component of cy-
toskeletonaswellasmitochondrialfunction[61].Usinghead
and neck squamous cell carcinoma cell lines, it has been
shownthatcisplatinformsadductswithmtDNAmoreabun-
dantly than those with nuclear DNA and binds preferentially
to mitochondrial membrane proteins [62]. Changes of mi-
tochondria and their function are associated mainly with in-
duction of intrinsic apoptotic pathway. Alteration on mito-
chondria membrane level (dissipation of MMP), release of
mitochondrial proteins into cytosol, and production of reac-
tiveoxygenspeciesareassociatedwithactivitiesofBcl-2fam-
ily proapoptotic and antiapoptotic proteins and activation of
caspases [62].
Invarioustypesofcancercells,mitochondrialalterations
have been shown to be associated with platinum-drug re-
sistance. The mitochondria of intrinsically resistant human
ovarian cancer cell lines and resistant clones of HeLa cells
showed altered morphology and were fewer in number. In
these models, cisplatin resistance was associated with lower
platinum accumulation and mitochondrial defects [63]. It
has been shown that density of mitochondria in intestinal
epithelial cells is the key factor for the determination of the
anticancer activity and side eﬀects of cisplatin [64]. Next,6 Metal-Based Drugs
elevation of MMP in ovarian cancer cells with acquired plat-
inum resistance has been observed, suggesting that changes
at the mitochondrial level would aﬀect the relative resistance
of malignant cells to undergo drug-induced apoptosis [65].
Impairment of mitochondrial apoptotic signaling pathway
is responsible for incomplete caspase-3 activation and lower
sensitivity of gastric cancer cells to cisplatin [66].
The upregulation of the antiapoptotic Bcl-2 protein con-
tributed to the development of cisplatin resistance, which
was reversed by Bcl-2 siRNA [67]. On the other hand,
targeted inactivation of proapoptotic Bax in colon cancer
HCT116 cells resulted in a signiﬁcantly increased resistance
to cisplatin [68]. Failure of caspase-9 activation induced a
higher threshold for apoptosis and cisplatin resistance in tes-
ticular cancer [69]. Resistance to apoptosis correlated with
the reduced caspase-3 activation and enhanced the expres-
sion of antiapoptotic proteins in human cervical multidrug-
resistant cells [70]. Furthermore, caspase-2 is known to me-
diate the recruitment of the mitochondrial apoptotic path-
wayuponDNAdamageinducedbychemotherapy(reviewed
in [44]). Cisplatin has been shown to induce p53-mediated
caspase-2 activation resulting in the mitochondrial release of
the apoptosis-inducing factor (AIF) and subsequent apopto-
sisinrenaltubularepithelialcells[71].Fromtheinformation
described above, it follows that the knowledge of platinum
drug eﬀects on mitochondria may help to design strategies
for increase of the eﬀectiveness of tumor cell treatment. Im-
portantly, similar approaches might be potentially used to
improve eﬃcacy of both currenly used platinum derivatives
and novel compounds, such as LA-12.
7. CHEMOTHERAPY AND OXIDATIVE METABOLISM
Studies in a variety of cell types have suggested that chem-
otherapeutic drugs induce cancer cell apoptosis at least in
part by inducing formation of ROS. In several cancer cell
models it has been demonstrated that cisplatin promotes
increased production of ROS, which can activate nuclear
factor-kappaB (NF-κB). This can lead to increased expres-
sion of proinﬂammatory mediators and intensify the cyto-
toxic eﬀects of cisplatin [72]. A positive correlation has been
reported between lipid peroxidation and the declined sur-
vival rate of murine melanoma cells after treatment with
novel platinum(II) complexes [73]. On the other hand, in B
lymphoma cells the cisplatin-induced apoptosis occurs via a
mechanism not involving oxidants [74]. Similarly, in mouse
ﬁbrosarcoma and human astrocytoma cells, cisplatin caused
oxidative stress-independent apoptotic cell death. Impor-
tantly, in the same cell systems, overproduction of ROS was
detected after treatment with the novel platinum(IV) com-
plex with a higher cytotoxicity compared to cisplatin, which
induced primarily necrosis [75].
Nevertheless, the role of oxidative metabolism associated
with the action of metal-based cytostatics is still rather con-
troversial. Production of ROS and generation of lipid perox-
ides (LP), and thus induction of oxidative stress, are consid-
eredtobesomeofthemaincausesofmetal-baseddrugorgan
toxicity, especially nephrotoxicity and hepatotoxicity [76].
Antioxidantscanreduceorpreventmanyofthesesideeﬀects.
In this context, the beneﬁcial eﬀects of compounds with an-
tioxidative properties like resveratrol or green tea have been
demonstrated [77].
It seems evident that the production and role of ROS and
LP in the eﬀects of platinum drugs may depend on the struc-
ture and concentration of the drug, the cellular system used,
the capacity of the antioxidant system, and can be further
modulated by the presence of other factors like TNF, which
may alter oxidative/antioxidative balance [78].
8. INTERACTIONS OF PLATINUM-BASED DRUGS
WITH CELL MEMBRANES AND WITH LIPID
SIGNALING/METABOLISM
8.1. Impactofpolyunsaturatedfattyacids(PUFAs)
onanticancerdrugeffects
There is increasing interest in the new therapeutic ap-
proaches based on the knowledge of structure, function, and
alteration of membrane lipids [79]. Experimental data in
vitro and in vivo and also several preclinical studies have
shownthatcertainPUFAs,especiallyofomega-3type(found
in marine plankton, ﬁsh oil, and some plant oils), possess
anticarcinogenic activities including suppression of neoplas-
tic transformation, cell growth inhibition, enhanced apop-
tosis, and antiangiogenicity especially in colon, breast, and
prostate tissues. This topic is behind the scope of our re-
view and many reviews have been published until now [80–
82]. Therefore, we pay attention mostly to the mechanisms,
which couldbe considered in possible anticancer strategy us-
ing combined treatment with cytostatics and PUFAs.
Several molecular mechanisms whereby omega-3 PU-
FAs may modify carcinogenic process have been proposed.
These include suppression of biosynthesis of arachidonic
acid-derived eicosanoids (especially due to decreased COX-
2 expression and activity), modulation of membrane prop-
erties and signal transduction pathways, eﬀects on tran-
scription factor activity, gene expression, alteration of es-
trogen metabolism and insulin sensitivity, and increased or
decreased production of reactive oxygen and nitrogen radi-
cals [83, 84] (for more details see below). Supplementation
of tumors with long-chained omega-3 PUFAs results in en-
richmentoftumorphospholipidfractionswiththesePUFAs.
Such cells then possess membranes with increased ﬂuidity,
anelevatedunsaturationindex,enhancedtransportcapabili-
ties that result in accumulation of selective anticancer agents,
increased activity of selected drug-activating enzymes, and
alteration of signaling pathways important for cancer pro-
gression. These changes may enhance tumor responsiveness
to antineoplastic agents such as doxorubicin, mitomycin C,
or 5-ﬂuorouracil [10, 85, 86], especially in tumor lines that
are resistant to chemotherapy. Studies of associations be-
tween the levels of fatty acids, especially docosahexaenoic
acid (DHA) stored in breast adipose tissue and the tumor
response to various chemotherapeutic agents in breast car-
cinoma patients suggest that increased DHA content may
improve therapeutic eﬀects [87]. There are several reports
demonstrating possibilities of enhancement of cisplatin cy-
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in ovarian A2780, breast MCF-7, and small cell lung GLC4-
sensitive and GLC4-resistant cancer cell lines [11, 12, 88].
The anticancer activity of cisplatin has been shown to be ef-
fectively supported by ﬁsh-oil diet under a conditioned bal-
ance of oxidation and antioxidation adjusted by vitamins E
a n dC[ 89]. Therefore, it appears that dietary administration
of omega-3 PUFAs might be a relatively nontoxic form of
cancer-supporting therapy increasing the eﬀects of various
anticancer agents including those based on platinum. In ad-
dition, certain PUFAs may also prevent or reduce some of
the side eﬀects of these therapies and tumor cachexia [90].
Therefore, it is important to study the mechanisms of the ef-
fectsofPUFAsandotherlipidmoleculesandtolookfortheir
links with cytostatic drug eﬀects.
8.2. Cellmembranepropertiesanddrugeffects
It has been shown that the levels of lipids in cell mem-
branes of cancer patients and in cancer cells resistant to
chemotherapy are altered [91, 92]. Nevertheless, the impor-
tance of cell membrane composition/properties and their
modulation for the eﬀects of platinum drugs is not clear. It
has been found that cisplatin-resistant epidermal cells have
a higher membrane potential and more ﬂuid membranes
than cisplatin-sensitive cells [93]. On the other hand, no dif-
ferences have been found in major phospholipids (PLs) or
in free cholesterol content between cisplatin-resistant and
cisplatin-sensitive human ovarian carcinoma cells. The de-
creased cisplatin accumulation in resistant cells is proba-
bly not due to membrane changes, which might lead to
retardation of passive diﬀusion of the drug into the cells
[94]. It has been demonstrated that cisplatin may interact
and form complexes with negatively charged PLs like phos-
phatidylserine and could change ﬂuidity of the membranes
[95, 96]. Modulation of membrane lipid composition and
metabolism may be important for cell behaviour, especially
in tumor cells, as their cell membranes are characterized by
changes in PL constituents and membrane ﬂuidity, namely,
by a decreased content of PUFAs [97]. All above studies seem
to suggest that modulation of cell membrane composition
and functions might modulate the eﬀects of platinum-based
drugs.
8.3. MechanismsofPUFAseffects
The mammalian organism is not able to synthesize PUFAs
and thus they have to be supplied in the diet. These essential
PUFAs play an important role in transducing signals from
the extracellular space and function as inter- and intracellu-
lar mediators and modulators of the cellular signaling net-
work [98]. Their eﬀects on various levels of cell organization
and their interaction with other endogenous or exogenous
factors can ﬁnally signiﬁcantly inﬂuence cell proliferation,
diﬀerentiation, and apoptosis [99].
The mechanisms of action of PUFAs are not yet fully un-
derstood and are likely to be very complex. The main mech-
anisms at the cellular level might include:
(1) incorporation of PUFAs into cancer cell membranes,
thus altering their physical and functional properties
and modulating signaling pathways involved in the
regulation of cytokinetics; changes in membrane com-
position further determine the ability of associated
proteins, such as receptors, ion channels, and so forth,
to move and interact;
(2) alterationofcelloxidativemetabolismduetolipidper-
oxidation and production of ROS or reactive nitrogen
species (RNS);
(3) conversion to their reactive and biologically active
metabolites (e.g., eicosanoids);
(4) activation of speciﬁc nuclear receptors and transcrip-
tion factors leading to altered expression of genes in-
volved in proliferation, diﬀerentiation, and apoptosis
(cytokinetics);
(5) interaction with other signal transduction pathways.
The most important of the above mechanisms are discussed
below.
8.4. PUFAsandlipideffectsoncellmembranelevel
As components of membrane PLs, PUFAs cause changes of
membrane ﬂuidity and remodeling of membrane structure,
which may inﬂuence receptor-ligand interactions, signal
transduction properties, and various aspects of membrane-
mediated cellular functions [100].
PUFAs, particularly DHA as the longest and most un-
saturated acyl chain commonly found in membranes, are
thought to be essential components of lipid rafts which rep-
resent small dynamic plasma membrane microdomains of
tightly packed proteins and lipids enriched with cholesterol
and sphingolipids [101, 102] .T h e s es t r u c t u r e sa r ef u n c t i o n -
ally implicated in the compartmentalization, modulation,
and integration of cell signaling, thus modulating impor-
tant processes including cell growth, survival, and adhesion
[103]. Sphingolipids constitute a class of lipids that may
function as second messengers in diﬀerent cellular processes
as cell diﬀerentiation, growth, and death. In particular, ce-
ramides have been implied in intracellular signal transduc-
tion systems regulating cellular diﬀerentiation, survival, and
apoptosis, and thus appear capable of changing the lifestyle
of virtually any cell type. Their production by sphingomyeli-
nases(SMase)canplayapivotalsignalingrolethroughdirect
interactionwithsignalingproteinsorthroughfacilitatingthe
formation and traﬃcking of signal transduction complexes
[104]. As components of lipid rafts, EPA and DHA might in-
crease the activity of SMase and the production of ceramide
in breast cancer cells simultaneously decreasing the level of
EGF receptors in lipid rafts, thus altering EGFR signaling
and inhibiting cancer cell growth [105]. Apoptotic stimuli,
such as death ligands or chemotherapeutic agents, can also
activate SMases and generate ceramide [106]. Based on these
ﬁndings, PUFAs might modulate function of proteins bound
to membrane lipid domains including the transporter func-
tionofproteinslikeP-glycoprotein(P-gp).Thelipidphaseof
the plasma membrane plays an important role with respect
to MDR and P-gp, whose activity is highly sensitive to lipid8 Metal-Based Drugs
environment. P-gp may also be involved in lipid traﬃcking
and metabolism. PUFAs play a speciﬁc structural function
in membranes and are capable of positioning a double bond
into the inner leaﬂet of a membrane. There is not much in-
formation about direct eﬀects of PUFAs on P-glycoprotein
expression and activity. The available data suggest that DHA
enhanced bioavailability of CYP3A substrates in the rat in-
testine, but did not inhibit P-gp [107]. In mouse leukemia
celllineP388GLAandDHApretreatmentimproveddoxoru-
bicin (DOX) cytotoxicity due to enhanced DOX accumula-
tion and changes of antioxidant enzyme activities. However,
no changes of P-gp expression were observed [108]. Promis-
ing results were achieved using fatty acid diesters, which are
more potent in reversing MDR in vitro due to their direct
P-gp binding properties [109].
8.5. PUFAsandmitochondria
Apart from the cytoplasmic membrane, PUFAs also physi-
cally interact with mitochondrial membranes and alter their
permeability by opening the permeability transition pores
and decreasing MMP [110]. Apoptotic signals depend on re-
dox catalytic interactions of cytochrome c with main mito-
chondrial PLs: cardiolipin and phosphatidylserine [111]. It
has been demonstrated that in colonocytes, DHA is prefer-
entially incorporated into cardiolipin, which coincides with
increasing unsaturation, induction of oxidative stress, release
of cytochrome c, and apoptosis [112]. PUFAs have also been
shown to signiﬁcantly modulate the level of several Bcl-2
family proteins (e.g., Bid, Bcl-2) interacting with mitochon-
drial membrane lipids which regulate apoptosis; cardiolipin
has been proposed to be a “lipid receptor” of Bid [113].
8.6. PUFAsandoxidativemetabolism
Antiproliferative and apoptotic eﬀects of PUFAs were shown
to be associated with changes on mitochondria and induc-
tion of oxidative stress. Susceptibility of their double bonds
to oxidation is the reason for production of various types
of biologically active metabolites like eicosanoids, ROS and
RNS,andlipidperoxides(LPs)[114].Wetogetherwithmany
others have shown that supplementation of cultured cells
with PUFAs dose-dependently enhanced ROS production
and lipid peroxidation [115, 116]. Many studies have doc-
umented that PUFAs augmented free radical generation and
formation of LPs selectively in the tumor cells compared to
normal cells despite the fact that the uptake of fatty acids
in the tumor cells was lower [117] .T h e r ei sac l o s ec o r r e -
lation between the rate of lipid peroxidation and the degree
of malignancy of tumor cells, and the susceptibility to ROS-
induced cytotoxicity. Dividing cells show low levels of lipid
peroxidation as compared to slowly dividing or nondivid-
ing cells. Resistance to lipid peroxidation appears to occur
at the premalignant stage of the carcinogenic process. ROS
also serve as common messengers downstream of various
stimulus-speciﬁc pathways leading to NF-κB activation, in-
cluding TNF-α, PUFAs, or cyclooxygenases (COXs), and are
involvedintheregulationofimmuneresponse,proliferation,
and apoptosis [118, 119].
Taken together, ROS and LPs can function as a “double-
edged sword.” Their excess may damage normal cell popu-
lations, while they may have antiproliferative and apoptotic
eﬀectsincancercellpopulation[97].Theseeventsmayinter-
ferewiththemodulationofoxidativemetabolisminducedby
platinum-based anticancer drugs, as described earlier.
8.7. EffectsofPUFAsonsignaltransduction
andgeneexpression
PUFAs and their metabolites are involved in many intra-
cellular signaling pathways activating or inhibiting various
components of this machinery and modulate gene expres-
sion [120]. They may alter the levels and signaling path-
ways of various mediators, such as eicosanoids and cytokines
[46, 115, 121].
The increase of phosphatidylserine by DHA resulted in
a modiﬁcation of the PI3K/Akt pathway, which is a ma-
jor signaling pathway mediating proliferative and diﬀeren-
tiation signals in many cell types in vitro and in vivo. ω-3
PUFAs decrease cell proliferation and induce apoptosis pos-
sibly by decreasing signal transduction through the Akt/NF-
κB cell survival pathway. In addition, PUFA-mediated mod-
ulation of other signaling pathways, such as those involv-
ing protein kinase C, extracellular signal-regulated kinase,
and p38 mitogen-activated protein kinase, has been reported
[122]. Fatty acids and their metabolites are generally con-
sidered as agonists of peroxisome proliferator-activated re-
ceptors (PPARs). Furthermore, PUFAs can also interact with
other transcription mediators including NF-κB[ 120]. PPAR
and NF-κB activation can be further associated with the reg-
ulation of expression of COX-2, an enzyme playing an im-
portant role in many pathological conditions [123].
Several studies using in vitro cell cultures have conﬁrmed
that certain PUFAs have a selective cytotoxic or antiprolifer-
ative eﬀect on tumor cells and a minimal or no eﬀect on nor-
mal cells. However, often cells from diﬀerent species and dif-
ferent tissues were compared. The eﬀects of PUFAs also de-
pend on time of treatment, concentration, and culture con-
ditions such as growth rate, cell conﬂuency, type of medium,
and amount of serum [124]. Nevertheless, it has been shown
that the fatty acid composition of tumor tissues diﬀers from
normal ones and that also activities of fatty acid metabolism
enzymes and oxidative defence were distinct. Tumor cells
are characterized by the loss or decreased activity of desat-
urases and thus a decreased metabolism of precursor omega-
6 linoleic acid and omega-3 α-linolenic acid to longer chain
fatty acids such as AA or EPA and DHA. They also have
a low level of cytochrome P450 enzymes which can initi-
ate and propagate lipid peroxides. Moreover, malignant cells
have markedly enhanced levels of antioxidants and low levels
of superoxid dismutase, glutathione peroxidase, and catalase
enzymes. These properties may be prerequisite for tumor-
selective augmentation of free radical generation and forma-
tion of lipid peroxides compared to normal cells after exoge-
nous addition of PUFAs. These products of PUFA oxidative
metabolism are powerful inducers of p53 activity, inﬂuence
the expression and activity of members of the Bcl-2 fam-
ily, activate caspases, and shorten telomeres, thus inducingAlois Kozub´ ık et al. 9
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Figure 2: A diagram depicting potential innovative chemotherapy strategies which might be employed to increase eﬃcacy of novel plat-
inum(IV) complexes.
apoptosis of cancer cells. They were also shown to play a role
in the metastatic process and angiogenesis [97]. Recently de-
veloped animal models can closely mimic the clinical course
of carcinogenesis and showed that it is especially the ratio of
omega-3 to omega-6 PUFAs which plays an important role
in cancer development [125]. The data from multiorgan car-
cinogenesis model in male rats treated with various types of
PUFAs provide evidence of their organotropic eﬀects on car-
cinogenesis,whichcorrelateswithreductionoftissueAAlev-
els in the target organs [126]. It was reported that PUFAs are
potent inhibitors of hepatic glycolysis and de novo lipogene-
sis and promote a shift from fatty acid synthesis and storage
tooxidationinhibiting lipogenicgenesthroughspeciﬁctran-
scription factors SREBP-1 and ChREBP [127]. Thus, further
studies evaluating especially the eﬀects of PUFAs on tumor
versus normal cells and tissues using in vivo systems are nec-
essary before copper-bottomed therapeutic use of omega-3
PUFAs for cancer patients. The future promising approaches
include use of new PUFA analogues [109] and the develop-
ment of speciﬁc conjugates of PUFAs with cytostatic drugs.
In tumor-bearing mice, it has been demonstrated that con-
jugates of DHA with taxanes are stable in plasma for a long
time, are less toxic than taxanes alone, and posses signiﬁ-
cantly increased antitumor activity [128, 129]. Recently, the
new conjugates of second generation of taxoids with DHA
exhibited strong activity against drug-resistant colon cancer
and drug-sensitive ovarian cancer xenografts in mice [130].
9. TARGETING OF CISPLATIN-BASED DRUGS
New strategy of development of PUFA-anticancer drug con-
jugates might be based on the fact that some PUFAs are
taken more rapidly by tumor cells than by normal cells. The
new DHA-taxoid conjugates exhibit a strong activity against
drug-resistant colon cancer and drug-sensitive ovarian can-
cer xenografts in mice and a reduced systemic toxicity as
compared to taxoids alone [130]. It might be speculated
that agents with higher lipophilicity, such as LA-12, would
be more eﬀective in suppression of proliferation and induc-
tion of cell death in the conditions of modulated phospho-
lipid metabolism. The above-mentioned eﬀects should be
taken into account when developing new strategies targeting
platinum-based drugs. Encapsulation in liposomes and link-
ing of cytotoxic platinum drugs to macromolecular carriers
are strategies for targeting to solid tumors. Eﬀective accumu-
lation of drug carriers in the tumor requires a long half-time
in circulation as well as an appropriate size of carriers (lipo-
somes or polymers), which should be below 120nm to pen-
etrate into the tumor tissue through fenestrations in the vas-
culature of capillary vessels nourishing the tumor. The extra-
cellular matrix represents another hindrance in the penetra-
tionofdrugcarriersdeepintothetumortissue[131].Alipo-
somal cisplatin preparation SPI77 has been studied in both
pediatric and adult patients, but the liposomes used were
too stable and cisplatin was insuﬃciently released from them
[132]. An improved liposomal cisplatin termed lipoplatin
[133] is about to enter phase III studies, and liposomal oxali-
platin is expected to enter the clinical stage of development
in the near future [134].
Several cisplatin derivatives with long alkyl chains were
prepared to improve their direct incorporation into the
liposomal membrane. Preliminary evidence of antitumor
activity of L-NDDP (liposomal formulation of cis-bis(neo-
decanoato)(trans-R,r-cyclohexane-1,2-diamine)platinum(II))
was reported from a phase II trial in refractory metastatic
colorectal cancer [135]. Nevertheless, clinical development
has been halted in order to improve drug formulation.
10. OTHER MECHANISMS
Although this review is dedicated principally to the role of
lipidsandpossibilitiesofmodulatingtheeﬀectsofnovelplat-
inum derivatives, we would also like to brieﬂy touch the is-
sues of inhibition of intercellular communication and possi-
bilities of modulation of multidrug resistance.
10.1. Modulationofgap-junctionalintercellular
communicationbyplatinumderivatives
Intracellular communication through gap junction (GJIC)
has been shown to be crucial for both tissue and cellular
homeostasis. Disruption of GJIC through defects in expres-
sion, posttranslational modiﬁcation, and localization of con-
nexins and/or mutation of genes coding for connexins seems
to be one of the mechanisms involved in carcinogenesis10 Metal-Based Drugs
[136]. Many chemopreventive and antitumor agents upreg-
ulate GJIC, which can be a signiﬁcant mechanism of their ef-
fects [137]. On the other hand, tumor promoters (e.g., phor-
bol esters, dithiothreitol) and also some anticancer drugs
such as doxorubicin, taxol, and also cisplatin decrease GJIC
[138–140]. Our own data indicate that disturbance of tis-
sue homeostasis owing to inhibition of GJIC may be linked
to a direct cytotoxic eﬀect of platinum drugs, rather than
an indirect eﬀect found for some carcinogens (e.g., TPA)
or polyaromatic tumor promoters [24]. It has been shown
that the increased level of connexin 43 may signiﬁcantly
improve the eﬃciency of anticancer therapy [141–143]; the
level of connexin 43 expression correlates with the sensitiv-
ity to anticancer therapy and the quality of regeneration af-
ter the therapy [141, 144] .T h e s es t u d i e ss t r o n g l ys u p p o r t
the importance of “bystander” cells and functional GJIC in
cancer therapy and recovery [145, 146]. Interestingly, it has
beenshownthatcisplatincaninducecell-interdependentcell
death through Ku/DNA-dependent protein kinase signaling
in mouse embryonic ﬁbroblasts [147]. Inhibition of GJIC
mightthussigniﬁcantlylimititseﬃciencyintargetcells,sug-
gesting that restoration of GJIC in tumor cells or prevention
of inhibitory eﬀects of anticancer drugs on GJIC might in-
crease the eﬀectiveness of both established and novel plat-
inum derivatives. This area of research presents a challenge
for the development of new drugs and/or treatment proto-
cols, which would lead to elimination of these side eﬀects.
10.2. Roleofresistanceinresponseto
platinumderivatives
Resistanceisamajorproblemintheapplicationofplatinum-
based therapy. The postulated mechanisms of cisplatin
resistance include reduced drug accumulation by changing
the proﬁle of uptake/eﬄux, inactivation of cisplatin by in-
creased levels of intracellular thiols such as glutathione, met-
allothionein, or other sulfur-containing molecules, increased
repair of cisplatin adducts, increased tolerance to cisplatin
adducts, and failure of apoptotic response. Reduced intracel-
lular drug accumulation in resistant cells might be ascribed
to an inhibition of drug uptake, an increase in drug eﬄux, or
both.Resistancetocisplatincanbeacquiredthroughchronic
drug exposure or it can present itself as an intrinsic phe-
nomenon. The results from our laboratory showed a great
potential of LA-12 to overcome both acquired [22] and in-
trinsic resistance in ovarian cancer cells [25]. The mecha-
nisms enabling LA-12 to defeat platinum resistance are cur-
rently unknown. However, they might be related to a num-
ber of events, including enhanced accumulation of the drug,
strong inhibition of DNA polymerization, decreased DNA
repair, and formation of DNA-protein cross-links as com-
pared to cisplatin [26].
The development of alternative platinum analogues or
their application, in combination with drugs acting through
diﬀerent mechanisms, seems to be an eﬀective strategy,
which would help to solve problems of cisplatin resistance.
However, this strategy usually fails in cases when the resis-
tance of the cells is due to their inability to die by apop-
tosis, which is not directly drug-dependent [148]. Interest-
ingly, LA-12 is able to induce not only apoptosis, but also a
caspase-independenttypeofcelldeath[25].Thiscouldbean
advantage when using this novel platinum(IV) agent for the
treatment of tumors with defects in the classical apoptotic
pathway.
Another strategy to address the problem of cisplatin
resistance is drug resistance reversal therapy [149]. This
therapy is simply focused on restoration of sensitivity to
platinum-based drugs through targeting of known mecha-
nisms of resistance using speciﬁc inhibitors of inﬂux, eﬄux
channels and transporters, glutathione-S-transferase, DNA
repair, p53 pathway, and so forth. It is currently not known
whether such strategies would also increase the eﬃciency of
LA-12 and related compounds.
11. CONCLUSION
Morethanthirtyyearsofexperimentalandclinicalstudieson
platinum-derived compounds have led to the development
of potent anticancer drugs. However, despite the progress
within this ﬁeld, treatment of generally more resistant types
of cancer, such as colon or prostate cancer, by more eﬃ-
cient cisplatin compounds still remains elusive. Recently de-
veloped platinum(IV) complexes with adamantylamine have
the potential for a signiﬁcantly improved therapy of many
types of tumors. Based on the ﬁndings discussed above, we
propose that several innovative approaches might be used to
modulate the anticancer eﬀects of platinum(IV) complexes
withadamantylamine.Thesemayinclude,forexample,com-
bined application with PUFAs and/or death ligands, or mod-
ulation of intercellular communication. Although suﬃcient
data on the role of endogenous regulators in the mechanism
of action of platinum-based drugs in the regulation of mam-
malian cell kinetics (proliferation, diﬀerentiation, and apop-
tosis) are currently limited, the role of PUFAs in modulat-
ing these processes should be emphasized, as summarized
in Figure 2. A possible potentiation of platinum-based drug
eﬀects by relatively cheap PUFAs from the diet and/or lipid
preparations would allow to decrease the doses of expensive
antineoplastic drugs, thus preventing side eﬀects and allow-
ing to use them also in low-sensitivity tumor types. Further
studies are needed to address these questions and to under-
stand the mechanisms involved.
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